Top Markets
#1 Akedo Akedo +179.90%
#2 TENDIES TENDIES +90.81%
#3 Threshold Network Threshold Network +48.52%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +28.98%
#6 Bitway Bitway +28.51%
#7 MultiversX MultiversX +25.94%
#8 Cash Cat Cash Cat +23.23%
#9 Palladium Network Palladium Network +22.70%
#10 aelf aelf +19.29%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Classifica tra le azioni #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prezzo delle azioni
$8.16
Ultima sincronizzazione: 2025-06-26
Capitalizzazione di mercato
$234.57M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Regulus Therapeutics Inc. (RGLS)

Categoria

Healthcare
Rapporto P/S per Regulus Therapeutics Inc. (RGLS)
Rapporto P/S al September 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Regulus Therapeutics Inc., il rapporto P/S attuale (TTM) è 0.00. Alla fine del 2023, era pari a 0.00.
Storico del rapporto P/S per Regulus Therapeutics Inc. da 2010 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 4.72 109.88%
2019 2.25 -98.00%
2018 112.61 -92.50%
2017 1.50K 1,409.28%
2016 99.52 360.84%
2015 21.60 -76.58%
2014 92.22 534.60%
2013 14.53 256.69%
2012 4.07 5,109.59%
2011 0.08 -37.59%
2010 0.13 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH